Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Basti c Mohammad-Reza Mohammadi Shahin Akhondzadeh a The present study was designed to evaluate the efficacy and safety of l-carnitine as an adjuvant agent to risperidone in the treatment of autism spectrum disorder (ASD)-associated behaviors
[1] [2] It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists , which were originally developed for treating type 2 diabetes
The final decision depends on clinical appropriateness rather than cost or popularity alone
S.NamaziM
PMID: 31599840
As the initial excitement fades, investors and patients alike are asking harder questions: Do these platforms deliver measurable, sustained health outcomes
US$ 22.17
US$ 21.04
US$ 29.50
US$ 20.13
US$ 21.46
US$ 23.61
US$ 20.61
US$ 22.15
US$ 25.00
